120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
贝利尤单抗联合个体化中医治疗难治性儿童狼疮性肾炎：病例报告
Authors Deng L, Guo L, Tang Z, Xu K
Received 25 September 2025
Accepted for publication 2 January 2026
Published 28 January 2026 Volume 2026:19 567214
DOI https://doi.org/10.2147/JIR.S567214
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Peng Wang
Lihua Deng,1– 4,* Lin Guo,1– 4,* Zhuoting Tang,1– 4 Kefei Xu1– 4
1Department of Pediatrics, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430000, People’s Republic of China; 2Department of Pediatrics, Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, Hubei, 430000, People’s Republic of China; 3Hubei Shizhen Laboratory, Wuhan, 430000, People’s Republic of China; 4Hubei Provincial Key Laboratory of Research and Application of Liver and Kidney in Traditional Chinese Medicine, Wuhan, 430065, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Kefei Xu, Department of Pediatrics, Hubei Provincial Hospital of Traditional Chinese Medicine, No. 856 Luoyu Road, Hongshan District, Wuhan, Hubei Province, 430000, People’s Republic of China, Tel +86 027 87748603, Email xukefeixkf37@163.com Zhuoting Tang, Department of Pediatrics, Hubei Provincial Hospital of Traditional Chinese Medicine, No. 856 Luoyu Road, Hongshan District, Wuhan, Hubei Province, 430000, People’s Republic of China, Tel +86 027 87748603, Email zhuotingtangtztcv@126.com
Background: Pediatric lupus nephritis (LN) is characterized by rapid progression and presents considerable therapeutic challenges. Standard immunosuppressive regimens may be insufficient in refractory cases, which are often marked by frequent relapses and poor long-term outcomes. Belimumab, a monoclonal antibody targeting B lymphocyte stimulator (BLyS), and individualized traditional Chinese medicine (TCM) interventions have demonstrated respective benefits in LN management. This case report describes the clinical course of a child with refractory LN that was managed using an integrative approach combining belimumab with individualized TCM therapy.
Case Presentation: A pediatric patient with LN presented with persistent gross hematuria, conventional glucocorticoids immunosuppressants and hydroxychloroquine treatment failed to achieve adequate disease control. Subsequent administration of belimumab in combination with an individualized TCM formulation led to notable clinical improvement, including significant reductions in proteinuria and hematuria, along with a marked decline in systemic lupus erythematosus disease activity. Background medications were gradually tapered during the treatment course. No serious adverse effects were observed, and clinical remission was sustained throughout the follow-up period.
Conclusion: The combination of belimumab and individualized TCM may safely and effectively control refractory childhood LN, reduce corticosteroid dosage, and sustain remission; however, validation through studies with larger sample sizes is required.
Keywords: biologic agents, glucocorticoids, gross hematuria, immunosuppressants, integrative medicine, lupus nephritis
1Department of Pediatrics, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430000, People’s Republic of China; 2Department of Pediatrics, Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, Hubei, 430000, People’s Republic of China; 3Hubei Shizhen Laboratory, Wuhan, 430000, People’s Republic of China; 4Hubei Provincial Key Laboratory of Research and Application of Liver and Kidney in Traditional Chinese Medicine, Wuhan, 430065, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Kefei Xu, Department of Pediatrics, Hubei Provincial Hospital of Traditional Chinese Medicine, No. 856 Luoyu Road, Hongshan District, Wuhan, Hubei Province, 430000, People’s Republic of China, Tel +86 027 87748603, Email xukefeixkf37@163.com Zhuoting Tang, Department of Pediatrics, Hubei Provincial Hospital of Traditional Chinese Medicine, No. 856 Luoyu Road, Hongshan District, Wuhan, Hubei Province, 430000, People’s Republic of China, Tel +86 027 87748603, Email zhuotingtangtztcv@126.com
Background: Pediatric lupus nephritis (LN) is characterized by rapid progression and presents considerable therapeutic challenges. Standard immunosuppressive regimens may be insufficient in refractory cases, which are often marked by frequent relapses and poor long-term outcomes. Belimumab, a monoclonal antibody targeting B lymphocyte stimulator (BLyS), and individualized traditional Chinese medicine (TCM) interventions have demonstrated respective benefits in LN management. This case report describes the clinical course of a child with refractory LN that was managed using an integrative approach combining belimumab with individualized TCM therapy.
Case Presentation: A pediatric patient with LN presented with persistent gross hematuria, conventional glucocorticoids immunosuppressants and hydroxychloroquine treatment failed to achieve adequate disease control. Subsequent administration of belimumab in combination with an individualized TCM formulation led to notable clinical improvement, including significant reductions in proteinuria and hematuria, along with a marked decline in systemic lupus erythematosus disease activity. Background medications were gradually tapered during the treatment course. No serious adverse effects were observed, and clinical remission was sustained throughout the follow-up period.
Conclusion: The combination of belimumab and individualized TCM may safely and effectively control refractory childhood LN, reduce corticosteroid dosage, and sustain remission; however, validation through studies with larger sample sizes is required.
Keywords: biologic agents, glucocorticoids, gross hematuria, immunosuppressants, integrative medicine, lupus nephritis